Latest Friedreich's ataxia Stories
Scientists, physicians, patients, families, and community leaders from around the world will join together in Tampa Bay from September 4-6 for the Friedreich’s Ataxia Research Alliance’s (FARA)
'We Believe' is a viral social media campaign that sheds light on Friedreich's Ataxia, a rare genetic disease for which there is currently no treatment or cure.
AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich's ataxia to clinic DOWNINGTOWN, Pa., April 6, 2014 /PRNewswire-USNewswire/ -- The Friedreich's
EPI-743 gains key regulatory endorsement. Downingtown, PA, (PRWEB) March 19, 2014 Edison Pharmaceuticals announced today that the U.S.
EPI-743 in two phase 2 development studies for Friedreich's ataxia MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the United States
FDA approves IND for clinical trial in ultra rare orphan mitochondrial disease MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation
Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Downingtown,
EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that
EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb.
Exclusive Channel Collaboration Focused on DNA-based Therapeutics for Children and Adults with Friedreich's ataxia NEW YORK and GERMANTOWN, Md., Dec.
- totally perplexed and mixed up.